GenVec, Inc. (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company's development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria. In the area of animal health, it is developing vaccines against foot-and-mouth disease (FMD). The Company develops and commercializes its product candidates through collaborations. The Company's lead product candidate is CGF166. The Company's vaccine candidates include preventative vaccines against RSV and malaria, and a therapeutic vaccine for HSV. The Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:GNVC
CUSIPN/A
Phone+1-240-6320740
Debt
Debt-to-Equity RatioN/A
Current Ratio2.10
Quick Ratio2.10
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-3,748.25%
Return on Equity-648.22%
Return on Assets-271.77%
Miscellaneous
Employees15
Outstanding Shares2,270,000
Market Cap$0.00
GenVec (NASDAQ:GNVC) Frequently Asked Questions
What is GenVec's stock symbol?
GenVec trades on the NASDAQ under the ticker symbol "GNVC."
When did GenVec's stock split? How did GenVec's stock split work?
Shares of GenVec reverse split before market open on Thursday, December 1st 2016. The 1-10 reverse split was announced on Wednesday, November 16th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 30th 2016. An investor that had 100 shares of GenVec stock prior to the reverse split would have 10 shares after the split.
How were GenVec's earnings last quarter?
GenVec Inc (NASDAQ:GNVC) released its earnings results on Friday, November, 4th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.08) by $0.03. The biopharmaceutical company earned $0.17 million during the quarter, compared to analysts' expectations of $0.07 million. GenVec had a negative net margin of 3,748.25% and a negative return on equity of 648.22%. View GenVec's Earnings History.
What is the consensus analysts' recommendation for GenVec?
0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GenVec in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."
Who are GenVec's key executives?
GenVec's management team includes the folowing people:
- Wayne T. Hockmeyer Ph.D., Independence Chairman of the Board
- Douglas J. Swirsky, President, Chief Executive Officer, Corporate Secretary, Director
- William N. Kelley M.D., Independent Director
- Stefan D. Loren Ph.D., Independent Director
- Quinterol J. Mallette M.D., Independent Director
- Michael S. Richman, Independent Director
- Marc R. Schneebaum, Independent Director
Has GenVec been receiving favorable news coverage?
News headlines about GNVC stock have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. GenVec earned a media sentiment score of 0.11 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 43.70 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
How do I buy shares of GenVec?
Shares of GNVC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GenVec's stock price today?
One share of GNVC stock can currently be purchased for approximately $7.1930.
How can I contact GenVec?
GenVec's mailing address is 910 Clopper Rd Ste 220n, GAITHERSBURG, MD 20878-1353, United States. The biopharmaceutical company can be reached via phone at +1-240-6320740.
MarketBeat Community Rating for GenVec (NASDAQ GNVC)
MarketBeat's community ratings are surveys of what our community members think about GenVec and other stocks. Vote "Outperform" if you believe GNVC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNVC will underperform the S&P 500 over the long term. You may vote once every thirty days.
